Immunotherapy could treat nut allergies, results show
A new immunotherapy could treat patients with nut allergies, preliminary results show.
VLP Peanut, an immunotherapy developed by biotechnology company Allergy Therapeutics, reached its primary endpoint in the Phase I/IIa PROTECT trial, with results showing the immunotherapy was safe and well-tolerated. The treatment was evaluated in 48 patients, with a 2000-fold increase from the starting dose being well-tolerated in both peanut-allergic patients and healthy participants.
The benign safety profile of VLP Peanut is supported by the observed dose-dependent reduction in wheal size, following skin prick testing for the two lowest doses evaluated. Peanut-allergic patients also showed a strong immune-protective dose response in biomarkers at low cumulative doses, with dose-dependent suppression of basophil activation and a dose-dependent increase in protective Ara h2 IgG, aligned with a dose-dependent reduction in IgE binding to B-cells.
Data from healthy participants also supports the proposed mechanism of action of VLP Peanut. Preliminary blinded biomarker data collected three months after last dosing of peanut allergic patients indicates a sustained biomarker response.
Allergy Therapeutics intends to carry out a second interim analysis in peanut-allergic patients receiving the highest doses in due course. The trial is currently progressing to deliver the planned group unblinded skin prick test and biomarker results, together with longer-term biomarker and scheduled safety assessments for up to one year after last dosing.
“The PROTECT trial has now reached a key regulatory milestone with the primary safety endpoint achieved at the highest planned treatment dose,” said Manuel Llobet, Chief Executive Officer of Allergy Therapeutics.
“Safety and tolerability at these dose levels remain supportive, reinforcing our confidence in the short-course approach underpinning VLP Peanut.
“As we move into the final stages of follow-up and biomarker assessment, our focus is on translating these data into the next phase of clinical development. We thank all participants, investigators and clinical teams involved in the study.”
Preparations are now underway for the Phase IIb trial.
Bruno Quinney, Content Team, DDW
